ID: ALA5284615

Max Phase: Preclinical

Molecular Formula: C23H23NO5

Molecular Weight: 393.44

Associated Items:

Representations

Canonical SMILES:  O=C1/C(=C/c2ccc(OCCN3CCOCC3)cc2)Cc2cc3c(cc21)OCO3

Standard InChI:  InChI=1S/C23H23NO5/c25-23-18(12-17-13-21-22(14-20(17)23)29-15-28-21)11-16-1-3-19(4-2-16)27-10-7-24-5-8-26-9-6-24/h1-4,11,13-14H,5-10,12,15H2/b18-11+

Standard InChI Key:  VWIPVRYNEVNROZ-WOJGMQOQSA-N

Associated Targets(Human)

A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CCD 19Lu (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PANC-1 (6144 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSL Tclin Cathepsin L (3852 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSD Tchem Cathepsin D (3201 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 393.44Molecular Weight (Monoisotopic): 393.1576AlogP: 2.95#Rotatable Bonds: 5
Polar Surface Area: 57.23Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 6.65CX LogP: 3.16CX LogD: 3.09
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.73Np Likeness Score: -0.56

References

1. Altıntop MD, Özdemir A, Temel HE, Demir Cevizlidere B, Sever B, Kaplancıklı ZA, Akalın Çiftçi G..  (2022)  Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer.,  244  [PMID:36270087] [10.1016/j.ejmech.2022.114851]

Source